Maruti Suzuki Q2 FY2025 Results: A Challenging Quarter
Crude prices are higher and you nudge around 13,000 probably there will be some volatility where crude spikes to $ 46 / bbl.
Yesterday, it was a big buy, FII inflows for November almost $ 7 bn now.
FII bought Rs. 4,738 crore in the crash market yesterday.
Dollar strengthens slightly developed Mkts Vs EM trade. We can see a big rally in the Dow Jones & Dow Futures,
The EM market is also doing well but perhaps not as well as the Developed market.
The whole bank Nifty vs IT RIL trade is of the first sign in reversal, the way delivery selling was seen in ICICI, HDFC, etc were amusing.
On the other hand 1000 crores of delivery buying in RIL, 600 crores of delivery buying in Infosys, so that trade is making a bit of a comeback.
The overall texture is bought on dips perhaps for the next term you better focus on Nifty instead of Bank Nifty.
The Nifty is facing some congestion at 13,000 whereas Bank Nifty is facing some congestion at 30,000.
Midcaps index up 12.5% this month, still the go-to place.
The rally helps in the theme you have to identify the individual stocks and put money there.
Midcaps have 12.5% this month which has still got a lot of room in terms of Valuation, That's the big place to begin.
Pharma has made a big comeback led by Divi’s lab.
Pharma & diagnostic could be back in focus by Divis’s lab with testing which may impact health care.
AstraZeneca's biggest positive for the Indian market is the third vaccine now. The one that India at least was betting on the AstraZeneca vaccine.
It has shown 70% efficacy in the first dose and 90% efficacy on the two doses, and the Serum Institute is already in agreement to manufacture the vaccine in the global vaccine.